Guardian Life Insurance Company Of America Decreased Jpmorgan Chase & Co (JPM) Stake; Alnylam Pharmaceuticals (ALNY) Has 1.4 Sentiment

June 14, 2018 - By Marie Mckinney

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Logo

Alnylam Pharmaceuticals Inc (ALNY) investors sentiment decreased to 1.4 in 2018 Q1. It’s down -0.63, from 2.03 in 2017Q4. The ratio dived, as 129 investment professionals increased or opened new positions, while 92 sold and decreased stock positions in Alnylam Pharmaceuticals Inc. The investment professionals in our database now hold: 89.26 million shares, down from 90.18 million shares in 2017Q4. Also, the number of investment professionals holding Alnylam Pharmaceuticals Inc in top ten positions decreased from 9 to 6 for a decrease of 3. Sold All: 25 Reduced: 67 Increased: 86 New Position: 43.

Guardian Life Insurance Company Of America decreased Jpmorgan Chase & Co (JPM) stake by 29.92% reported in 2018Q1 SEC filing. Guardian Life Insurance Company Of America sold 3,410 shares as Jpmorgan Chase & Co (JPM)’s stock declined 6.83%. The Guardian Life Insurance Company Of America holds 7,986 shares with $878,000 value, down from 11,396 last quarter. Jpmorgan Chase & Co now has $368.06B valuation. The stock decreased 1.69% or $1.86 during the last trading session, reaching $108.11. About 13.13M shares traded. JPMorgan Chase & Co. (NYSE:JPM) has risen 29.65% since June 14, 2017 and is uptrending. It has outperformed by 17.08% the S&P500. Some Historical JPM News: ; 20/03/2018 – JPMorgan names Mellody Hobson to board; 25/05/2018 – EIDOS THERAPEUTICS INC SAYS J.P. MORGAN, BOFA MERRILL LYNCH, BARCLAYS ARE AMONG UNDERWRITERS TO IPO; 03/05/2018 – Cypress Semi Presenting at JPMorgan Conference May 15; 01/05/2018 – Buy EA on the dip because ‘Fortnite’ is less of a risk for game maker: JP Morgan; 26/03/2018 – Long-Term Dollar Fundamentals to the Downside Says JPMorgan (Video); 13/03/2018 – PARSLEY ENERGY INC PE.N : JP MORGAN RAISES TARGET PRICE TO $45 FROM $43; 15/05/2018 – Despegar.com Presenting at JPMorgan Conference May 17; 30/04/2018 – JPMorgan Growth Advantage Adds Deere, Exits Humana; 13/04/2018 – Investors & Innovators to Come Together at BioNJ’s BioPartnering Conference with J.P. Morgan; 10/04/2018 – NISOURCE INC Nl.N : JP MORGAN RAISES TARGET PRICE TO $25 FROM $23

The stock increased 4.48% or $4.6 during the last trading session, reaching $107.46. About 404,797 shares traded. Alnylam Pharmaceuticals, Inc. (ALNY) has risen 43.86% since June 14, 2017 and is uptrending. It has outperformed by 31.29% the S&P500. Some Historical ALNY News: ; 03/05/2018 – ALNYLAM PHARMACEUTICALS INC – IF LUMASIRAN PHASE 3 STUDY POSITIVE, AN NDA SUBMISSION ANTICIPATED IN EARLY 2020; 01/05/2018 – Alnylam Presenting at Conference May 17; 20/04/2018 – Alnylam Reaches Settlement Agreement With Dicerna Pharmaceuticals; 07/05/2018 – Medicines Co: Inclisiran Drove Sustained Lowering of Key Atherogenic Lipoproteins; 23/04/2018 – Alnylam Receives Positive Opinion for Orphan Drug Designation in the European Union for ALN-TTRsc02, a Subcutaneously Delivered; 20/04/2018 – Alnylam Reaches Settlement Agreement with Dicerna Pharmaceuticals Resolving Trade Secret Misappropriation and Other Pending; 11/05/2018 – Consolidated Research: 2018 Summary Expectations for STORE Capital, Microvision, International Game Technology, McKesson, Marin; 07/05/2018 – Medicines Co: Inclisiran Reduced Key Atherogenic Lipoproteins Back to Normal in 68% to 90% of Patient Studied; 26/03/2018 – Alnylam Pharmaceuticals Lumasiran Was Recently Granted Breakthrough Therapy Designation by the FDA; 20/04/2018 – Alnylam Reaches Settlement Agreement with Dicerna Pharmaceuticals Resolving Trade Secret Misappropriation and Other Pending Litigation

Analysts await Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to report earnings on August, 8. They expect $-1.71 earnings per share, down 27.61% or $0.37 from last year’s $-1.34 per share. After $-1.41 actual earnings per share reported by Alnylam Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 21.28% negative EPS growth.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. The company has market cap of $10.80 billion. The Company’s pipeline of investigational RNAi therapeutics is focused on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. It currently has negative earnings. The companyÂ’s clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of transthyretin-mediated amyloidosis ; Fitusiran, an investigational RNAi therapeutic that is in Phase I/II clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran (ALN-PCSsc), which is in Phase II clinical trial for hypercholesterolemia.

Ratings analysis reveals 57% of Alnylam Pharma’s analysts are positive. Out of 7 Wall Street analysts rating Alnylam Pharma, 4 give it “Buy”, 0 “Sell” rating, while 3 recommend “Hold”. The lowest target is $36.0 while the high is $137.0. The stock’s average target of $87.50 is -18.57% below today’s ($107.46) share price. ALNY was included in 7 notes of analysts from October 6, 2016. As per Thursday, October 6, the company rating was downgraded by Leerink Swann. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) earned “Buy” rating by Ladenburg Thalmann on Thursday, February 2. The rating was maintained by Chardan Capital Markets on Thursday, October 6 with “Buy”. On Thursday, October 6 the stock rating was maintained by FBR Capital with “Outperform”. The firm has “Neutral” rating by JP Morgan given on Thursday, October 6. Stifel Nicolaus maintained Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on Thursday, October 6 with “Hold” rating. Needham maintained the shares of ALNY in report on Thursday, October 6 with “Buy” rating.

More notable recent Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) news were published by: Seekingalpha.com which released: “Alnylam Pharmaceuticals Continues To Develop Options Outside Of Amyloidosis” on June 12, 2018, also Fool.com with their article: “Is Alnylam Pharmaceuticals, Inc. (ALNY) a Buy?” published on May 17, 2018, Seekingalpha.com published: “Alnylam’s lumasiran shows positive effect in Phase 1/2 PH1 study” on June 08, 2018. More interesting news about Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) were released by: Nasdaq.com and their article: “Better Buy: Bellicum Pharmaceuticals, Inc. vs. Alnylam Pharmaceuticals, Inc.” published on June 03, 2018 as well as Seekingalpha.com‘s news article titled: “Akcea And Ionis: What The Latest Regulatory Catalyst For Inotersen Foretells” with publication date: June 08, 2018.

Since January 1, 0001, it had 0 buys, and 11 insider sales for $39.55 million activity.

12 West Capital Management Lp holds 9.17% of its portfolio in Alnylam Pharmaceuticals, Inc. for 700,000 shares. Perceptive Advisors Llc owns 1.28 million shares or 4.27% of their US portfolio. Moreover, Bridger Management Llc has 3.97% invested in the company for 549,632 shares. The Switzerland-based Bb Biotech Ag has invested 3.33% in the stock. Opus Point Partners Management Llc, a New York-based fund reported 13,680 shares.

Analysts await JPMorgan Chase & Co. (NYSE:JPM) to report earnings on July, 13 before the open. They expect $2.25 earnings per share, up 23.63% or $0.43 from last year’s $1.82 per share. JPM’s profit will be $7.66B for 12.01 P/E if the $2.25 EPS becomes a reality. After $2.37 actual earnings per share reported by JPMorgan Chase & Co. for the previous quarter, Wall Street now forecasts -5.06% negative EPS growth.

More notable recent JPMorgan Chase & Co. (NYSE:JPM) news were published by: Seekingalpha.com which released: “JPMorgan (JPM) Management Presents at Morgan Stanley Financials Conference (Transcript)” on June 13, 2018, also Seekingalpha.com with their article: “US banks fall as ECB keeps rates unchanged, day after Fed raises” published on June 14, 2018, Thestreet.com published: “5 Reasons Why JPMorgan Will Be a Monster Trade” on May 30, 2018. More interesting news about JPMorgan Chase & Co. (NYSE:JPM) were released by: Themiddlemarket.com and their article: “M&A daily wrap: Rockwell, PTC, L Catterton, Splunk, Heineken, Knauf” published on June 11, 2018 as well as Bizjournals.com‘s news article titled: “Banking Roundup: Starbucks launches JPMorgan Visa cards… BofA’s virtual assistant Erica hits milestone” with publication date: June 13, 2018.

Investors sentiment decreased to 0.81 in Q1 2018. Its down 0.07, from 0.88 in 2017Q4. It worsened, as 52 investors sold JPM shares while 843 reduced holdings. 132 funds opened positions while 596 raised stakes. 2.39 billion shares or 2.61% less from 2.46 billion shares in 2017Q4 were reported. Jacobson And Schmitt Limited Liability Company holds 0.02% or 294 shares in its portfolio. Basswood Management Limited Liability accumulated 733,012 shares. Thomas Story And Son Ltd Liability Company reported 0.17% in JPMorgan Chase & Co. (NYSE:JPM). R G Niederhoffer Cap Mgmt Inc stated it has 7,200 shares. Reilly Herbert Faulkner Iii holds 1,834 shares. Int, New York-based fund reported 1.13 million shares. Boyar Asset Management invested 5.56% of its portfolio in JPMorgan Chase & Co. (NYSE:JPM). Chesapeake Asset Limited Liability has invested 3.68% in JPMorgan Chase & Co. (NYSE:JPM). Cypress Management Limited Liability Company invested in 130,686 shares. Stoneridge Inv Ptnrs Limited Co accumulated 120,826 shares. Skba Cap Mngmt Limited Liability Company holds 2.19% in JPMorgan Chase & Co. (NYSE:JPM) or 147,132 shares. Truepoint Inc invested in 0% or 393 shares. Lombard Odier Asset Mngmt (Usa) Corp holds 20,903 shares. C M Bidwell And Associates stated it has 3,180 shares or 0.32% of all its holdings. Synovus Financial Corporation holds 305,194 shares or 0.57% of its portfolio.

Since January 13, 2018, it had 3 insider purchases, and 8 insider sales for $18.63 million activity. Shares for $825,327 were bought by CROWN JAMES S on Tuesday, January 16. Scher Peter sold $3.01 million worth of stock or 26,532 shares. The insider BACON ASHLEY sold $1.84M. Another trade for 18,000 shares valued at $2.00M was made by HOBSON MELLODY L on Monday, April 16. On Saturday, January 13 the insider Giles Nicole sold $425,399. 65,101 shares were sold by Erdoes Mary E., worth $7.31M on Saturday, January 13. Another trade for 48,344 shares valued at $5.43 million was sold by Petno Douglas B.

Guardian Life Insurance Company Of America increased Ishares Tr (EEM) stake by 271,397 shares to 682,243 valued at $32.94 million in 2018Q1. It also upped Powershs Db Multi Sect Comm (DBO) stake by 911,259 shares and now owns 2.48M shares. Ishares Tr (EFA) was raised too.

Among 34 analysts covering JPMorgan Chase & Co (NYSE:JPM), 18 have Buy rating, 2 Sell and 14 Hold. Therefore 53% are positive. JPMorgan Chase & Co had 120 analyst reports since July 21, 2015 according to SRatingsIntel. RBC Capital Markets maintained JPMorgan Chase & Co. (NYSE:JPM) on Monday, November 13 with “Buy” rating. The rating was maintained by RBC Capital Markets on Thursday, June 15 with “Buy”. The rating was maintained by BMO Capital Markets with “Outperform” on Thursday, April 14. The firm earned “Buy” rating on Monday, January 18 by Argus Research. RBC Capital Markets maintained it with “Buy” rating and $95.0 target in Tuesday, September 26 report. As per Wednesday, September 7, the company rating was maintained by Nomura. The firm has “Neutral” rating by UBS given on Monday, January 18. Bank of America maintained it with “Buy” rating and $9900 target in Sunday, July 16 report. The stock has “Hold” rating by Keefe Bruyette & Woods on Thursday, December 21. The stock of JPMorgan Chase & Co. (NYSE:JPM) earned “Buy” rating by Wells Fargo on Wednesday, January 17.

JPMorgan Chase & Co. (NYSE:JPM) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Marie Mckinney

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:








Recent Posts